Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 5/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
| ▸ | CHKA | P35790 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28192273 | 0.85 | ALDH1A1 (0.96) | ALDH1A1HTTKDM4ESIGMAR1DPP4 | |
| SCHEMBL4101414 | 0.85 | ALDH1A1 (0.89) | ALDH1A1HTTKDM4ESIGMAR1DPP4 | |
| SCHEMBL26116727 | 0.84 | ALDH1A1 (0.51) | ALDH1A1HTTKDM4ESIGMAR1DRD4 | |
| SCHEMBL26118682 | 0.84 | ALDH1A1 (0.51) | ALDH1A1HTTKDM4ESIGMAR1DRD3 | |
| SCHEMBL26114415 | 0.84 | ALDH1A1 (0.51) | ALDH1A1HTTKDM4ESIGMAR1DRD2 | |
| SCHEMBL26117280 | 0.84 | POLB (0.51) | ALDH1A1HTTKDM4ESIGMAR1DRD3 | |
| SCHEMBL13293320 | 0.83 | ALDH1A1 (1.00) | ALDH1A1HTTKDM4ESIGMAR1DPP4 | |
| SCHEMBL16226262 | 0.81 | ALDH1A1 (0.71) | ALDH1A1HTTKDM4EDRD3DRD2 | |
| Hydrochloric Acid SCHEMBL7401709 | 0.81 | ALDH1A1 (0.96) | ALDH1A1HTTKDM4ESIGMAR1DPP4 | |
| SCHEMBL28817369 | 0.81 | ALDH1A1 (0.46) | ALDH1A1HTTKDM4ESIGMAR1CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023194964-A1 | FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-12 | — | — | WO | disclosed |
| EP-1212299-B1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LTD (GB) | 2009-04-08 | — | — | EP | disclosed |
| US-20050250792-A1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | MERRILL LYNCH CAPITAL, A DIVISION OF MERRILL LYNCH BUSINESS FINANCIAL SERVICES, INC. AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | disclosed |
| US-6903085-B1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | ASTRAZENECA, AB (CH) | 2005-06-07 | — | — | US | disclosed |
| EP-1212299-A1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca UK Limited (GB) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001014333-A1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LIMITED (GB) | 2001-03-01 | — | — | WO | disclosed |
| EP-0625507-B1 | Urea derivatives and their use as acat inhibitors | NISSHIN FLOUR MILLING CO (JP) | 1997-07-23 | — | — | EP | disclosed |
| US-5621010-A | ANTIHYPERCHOLESTEROLEMIA AND ANTIATHEROSCLEROSIS | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1997-04-15 | — | — | US | disclosed |
| EP-0625507-A2 | Urea derivatives and their use as acat inhibitors | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1994-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250792-A1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | CXCR4, CXCR1, CXCR3 | ALDH1A1 1952/4885HTT 2931/4885KDM4E 2699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.